A Disintegrin And Metalloproteinase

From Proteopedia

spinqualitylabelsall models A Disintegrin And Metalloproteinase complex with sulfate 2ao7 Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image Function A Disintegrin And Metalloproteinase (ADAM) are peptidases which cleave off extracellular portions of transmembrane proteins. ADAM family members are numbered. ADAM10 cleaves ephrin. ADAM13 details are in Molecular Playground/ADAM13. ADAM17 (TACE or TNF-α converting enzyme) processes the tumor necrosis factor-α. ADAM33 is implicated in asthma. ADAMTS is ADAM with thrombospondin motifs[1]. ADAMTS1 has anti-angionenic activity[2]. ADAMTS4 and ADAMTS5 are involved in the degradation of aggrecan. ADAMTS13 cleaves Von Willebrand Factor involved in blood clotting[3]. Disease ADAM inhibitors are used in anti-cancer therapy. ADAM10 is a therapeutic target for cancer and inflammation [4]. ADAM17 is a therapeutic target for multiple diseases [5]. ADAM33 is implicated in asthma. ADAM33 is a therapeutic target for asthma [6]. ADAMTS4 is involved in various CNS pathologies[7]. 3D Structures of A Disintegrin And Metalloproteinase A Disintegrin And Metalloproteinase 3D structures

References

1. ↑ Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. Biochem J. 2005 Feb 15;386(Pt 1):15-27. PMID:15554875 doi:10.1042/BJ20040424
2. ↑ Shindo T, Kurihara H, Kuno K, Yokoyama H, Wada T, Kurihara Y, Imai T, Wang Y, Ogata M, Nishimatsu H, Moriyama N, Oh-hashi Y, Morita H, Ishikawa T, Nagai R, Yazaki Y, Matsushima K. ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function. J Clin Invest. 2000 May;105(10):1345-52. PMID:10811842 doi:10.1172/JCI8635
3. ↑ Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med. 2008 Oct;29(5):258-89. doi: 10.1016/j.mam.2008.08.001. Epub 2008, Aug 15. PMID:18762209 doi:http://dx.doi.org/10.1016/j.mam.2008.08.001
4. ↑ Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML. ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des. 2009;15(20):2288-99. PMID:19601831 doi:10.2174/138161209788682442
5. ↑ Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des. 2009;15(20):2319-35. PMID:19601834 doi:10.2174/138161209788682398
6. ↑ Sleziak J, Gawor A, Błażejewska M, Antosz K, Gomułka K. ADAM33's Role in Asthma Pathogenesis: An Overview. Int J Mol Sci. 2024 Feb 15;25(4):2318. PMID:38396994 doi:10.3390/ijms25042318
7. ↑ Lemarchant S, Wojciechowski S, Vivien D, Koistinaho J. ADAMTS-4 in central nervous system pathologies. J Neurosci Res. 2017 Sep;95(9):1703-1711. PMID:28084617 doi:10.1002/jnr.24021